Literature DB >> 31028291

Bufalin suppresses the migration and invasion of prostate cancer cells through HOTAIR, the sponge of miR-520b.

Jian-Jun Zhang1,2, Xiao-Hui Zhou3, Yan Zhou2, Yong-Gang Wang2, Bin-Zhi Qian4, Ai-Na He2, Zan Shen2, Hai-Yan Hu5, Yang Yao6.   

Abstract

Bufalin, the major active component of the traditional Chinese medicine ChanSu obtained from the skin and parotid venom glands of toads, has long been known as an anticancer agent. Recent studies show that microRNAs (miRs) are involved in the anticancer activities of bufalin, while long non-coding RNAs (lncRNAs) are known to interact with miRNAs to regulate various biological functions. In this paper, we investigated the possible network related to the antimetastatic effect of bufalin in prostate cancer (PCa) cells. We demonstrated that bufalin (0.05-10 µM) dose-dependently suppressed the proliferation of prostate cancer DU145 and PC3 cells with IC50 values of 0.89 and 1.28 µM, respectively. Furthermore, bufalin treatment significantly suppressed the cell migration and invasion. To explore the role of lncRNAs in the antimetastatic activity of bufalin, we used an lncRNA microarray and found that HOX transcript antisense RNA (HOTAIR) was the most markedly downregulated lncRNA in bufalin-treated PCa cells. Overexpression of HOTAIR counteracted the suppressing effects of bufalin on DU145 and PC3 cells. We then predicted and verified that HOTAIR upregulated FGFR1 expression by sponging miR-520b in PCa cells. In 40 patients with PCa bone metastasis, we used in situ hybridization or immunohistochemical assay to assess the HOTAIR and FGFR1 expression, which revealed that both HOTAIR and FGFR1 expression were significantly higher in bone metastasis tissues than in the primary PCa tissues. In addition, the level of serum HOTAIR was positively associated with the levels of serum bone metabolic markers (CTx, OST, B-ALP and PINP) and may serve as a reasonable biomarker for PCa bone metastasis. Taken together, this is the first study revealing that HOTAIR promotes PCa bone metastasis, and bufalin may be a promising candidate for the treatment of this disease.

Entities:  

Keywords:  FGFR1; HOTAIR; bone metastasis; bufalin; lncRNA; miR-520b; traditional Chinese medicine; prostate cancer

Mesh:

Substances:

Year:  2019        PMID: 31028291      PMCID: PMC6786369          DOI: 10.1038/s41401-019-0234-8

Source DB:  PubMed          Journal:  Acta Pharmacol Sin        ISSN: 1671-4083            Impact factor:   6.150


  37 in total

1.  Predictive factors for response to abiraterone in metastatic castration refractory prostate cancer.

Authors:  Mehran Afshar; Fawaz Al-Alloosh; Sarah Pirrie; Clare Rowan; Nicholas D James; Emilio Porfiri
Journal:  Anticancer Res       Date:  2015-02       Impact factor: 2.480

2.  Bufalin and cinobufagin induce apoptosis of human hepatocellular carcinoma cells via Fas- and mitochondria-mediated pathways.

Authors:  Fanghua Qi; Yoshinori Inagaki; Bo Gao; Xiaoyan Cui; Huanli Xu; Norihiro Kokudo; Anyuan Li; Wei Tang
Journal:  Cancer Sci       Date:  2011-02-28       Impact factor: 6.716

3.  Role of P53-Senescence Induction in Suppression of LNCaP Prostate Cancer Growth by Cardiotonic Compound Bufalin.

Authors:  Yong Zhang; Yinhui Dong; Michael W Melkus; Shutao Yin; Su-Ni Tang; Peixin Jiang; Kartick Pramanik; Wei Wu; Sangyub Kim; Min Ye; Hongbo Hu; Junxuan Lu; Cheng Jiang
Journal:  Mol Cancer Ther       Date:  2018-08-30       Impact factor: 6.261

4.  [Enhancement of all-trans retinoic acid-induced differentiation by bufalin in primary culture of acute promyelocytic leukemia cells].

Authors:  Zhi-tu Zhu; Bo Jin; Yun-peng Liu; Ying-chun Li; Xiang-lan Lu; Xin Tian; Ke-zuo Hou
Journal:  Zhonghua Nei Ke Za Zhi       Date:  2006-04

5.  Effects of bufalin on the proliferation of human lung cancer cells and its molecular mechanisms of action.

Authors:  Yongtao Jiang; Ying Zhang; Jinling Luan; Huiying Duan; Feng Zhang; Kazumi Yagasaki; Guoying Zhang
Journal:  Cytotechnology       Date:  2010-10-21       Impact factor: 2.058

6.  Cancer Statistics, 2017.

Authors:  Rebecca L Siegel; Kimberly D Miller; Ahmedin Jemal
Journal:  CA Cancer J Clin       Date:  2017-01-05       Impact factor: 508.702

7.  A bufadienolide derived androgen receptor antagonist with inhibitory activities against prostate cancer cells.

Authors:  Hai-Yan Tian; Xiao-Feng Yuan; Lu Jin; Juan Li; Cheng Luo; Wen-Cai Ye; Ren-Wang Jiang
Journal:  Chem Biol Interact       Date:  2013-11-05       Impact factor: 5.192

8.  Microarray and biochemical analysis of bufalin-induced apoptosis of HL-60 Cells.

Authors:  Ailiang Chen; Jian Yu; Liang Zhang; Yimin Sun; Yan Zhang; Hongyan Guo; Yuxiang Zhou; Keith Mitchelson; Jing Cheng
Journal:  Biotechnol Lett       Date:  2008-11-28       Impact factor: 2.461

9.  Cancer statistics in China, 2015.

Authors:  Wanqing Chen; Rongshou Zheng; Peter D Baade; Siwei Zhang; Hongmei Zeng; Freddie Bray; Ahmedin Jemal; Xue Qin Yu; Jie He
Journal:  CA Cancer J Clin       Date:  2016-01-25       Impact factor: 508.702

Review 10.  Prostate cancer and bone: the elective affinities.

Authors:  Nadia Rucci; Adriano Angelucci
Journal:  Biomed Res Int       Date:  2014-05-28       Impact factor: 3.411

View more
  10 in total

Review 1.  Traditional Chinese medicine reverses cancer multidrug resistance and its mechanism.

Authors:  J Wei; Z Liu; J He; Q Liu; Y Lu; S He; B Yuan; J Zhang; Y Ding
Journal:  Clin Transl Oncol       Date:  2021-10-13       Impact factor: 3.405

2.  Long Noncoding RNA HOTAIR Promotes Endometrial Carcinoma Cell Proliferation by Binding to PTEN via the Activating Phosphatidylinositol 3-Kinase/Akt Signaling Pathway.

Authors:  Xiao-Hui Zhang; Pin Hu; Yang-Qin Xie; Yong-Jun Kang; Min Li
Journal:  Mol Cell Biol       Date:  2019-11-12       Impact factor: 4.272

Review 3.  Functional Interaction among lncRNA HOTAIR and MicroRNAs in Cancer and Other Human Diseases.

Authors:  Monica Cantile; Maurizio Di Bonito; Maura Tracey De Bellis; Gerardo Botti
Journal:  Cancers (Basel)       Date:  2021-02-02       Impact factor: 6.639

Review 4.  HIF-1α Is a Rational Target for Future Ovarian Cancer Therapies.

Authors:  Xin Wang; Zhen-Wu Du; Tian-Min Xu; Xiao-Jun Wang; Wei Li; Jia-Li Gao; Jing Li; He Zhu
Journal:  Front Oncol       Date:  2021-12-24       Impact factor: 6.244

5.  Ailanthone Inhibits Proliferation, Migration and Invasion of Osteosarcoma Cells by Downregulating the Serine Biosynthetic Pathway.

Authors:  Yawen Zhang; Runze Gong; Yong Liu; Xipeng Sun; Jinrong Liang; Yan Zhou; Yaling Wang; Wenxi Yu; Yonggang Wang; Lina Tang; Aina He; Zan Shen; Yang Yao; Haiyan Hu; Xin Liu; Jianjun Zhang
Journal:  Front Oncol       Date:  2022-02-03       Impact factor: 6.244

Review 6.  Crosstalk between Long Non Coding RNAs, microRNAs and DNA Damage Repair in Prostate Cancer: New Therapeutic Opportunities?

Authors:  Folake Orafidiya; Lin Deng; Charlotte Lynne Bevan; Claire Emily Fletcher
Journal:  Cancers (Basel)       Date:  2022-01-31       Impact factor: 6.639

7.  The Integrated Study on the Chemical Profiling to Explore the Constituents and Mechanism of Traditional Chinese Medicine Preparation Huatuo Jiuxin Pills Based on UPLC-Q-TOF/MSE and Network Pharmacology.

Authors:  Yulong Zhu; Yaqin Zhu; Shuyue Tao; Wanhui Liang; Jing Zhang; Yunjing Zhang; Zihua Xuan; Jingjing Xu; Can Peng; Huan Wu; Deling Wu
Journal:  Front Mol Biosci       Date:  2022-03-31

Review 8.  Formation of pre-metastatic bone niche in prostate cancer and regulation of traditional chinese medicine.

Authors:  Chiwei Chen; Renlun Huang; Jianfu Zhou; Lang Guo; Songtao Xiang
Journal:  Front Pharmacol       Date:  2022-08-17       Impact factor: 5.988

Review 9.  Chemistry and the Potential Antiviral, Anticancer, and Anti-Inflammatory Activities of Cardiotonic Steroids Derived from Toads.

Authors:  Hesham R El-Seedi; Nermeen Yosri; Bishoy El-Aarag; Shaymaa H Mahmoud; Ahmed Zayed; Ming Du; Aamer Saeed; Syed G Musharraf; Islam M El-Garawani; Mohamed R Habib; Haroon Elrasheid Tahir; Momtaz M Hegab; Xiaobo Zou; Zhiming Guo; Thomas Efferth; Shaden A M Khalifa
Journal:  Molecules       Date:  2022-10-05       Impact factor: 4.927

10.  Application Value of Total Knee Arthroplasty plus Platelet-Rich Plasma Therapy in Traumatic Arthritis of the Knee.

Authors:  Canhong Zhang; Pengfei Nie
Journal:  Comput Math Methods Med       Date:  2022-09-26       Impact factor: 2.809

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.